IMV Valore dell'impresa
Cos'è Valore dell'impresa di IMV?
Valore dell'impresa di IMV, Inc. è $25.88M
Qual è la definizione di Valore dell'impresa?
Il valore dell'impresa è una misura del valore di mercato totale di un'azienda. È calcolato come capitalizzazione di mercato con debito, interessi di minoranza e azioni privilegiate al netto delle disponibilità liquide e mezzi equivalenti.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Valore dell'impresa di aziende nel Health Care settore su TSX rispetto a IMV
Cosa fa IMV?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Aziende con valore dell'impresa simili a IMV
- Volatus Aerospace Corp ha Valore dell'impresa di $25.84M
- Technologies ha Valore dell'impresa di $25.84M
- Bigblu Broadband plc ha Valore dell'impresa di $25.85M
- Fremont Petroleum ha Valore dell'impresa di $25.87M
- HighGold Mining ha Valore dell'impresa di $25.87M
- Asia Commercial ha Valore dell'impresa di $25.87M
- IMV ha Valore dell'impresa di $25.88M
- Bionomics ha Valore dell'impresa di $25.89M
- DMG Blockchain Solutions ha Valore dell'impresa di $25.89M
- Mallinckrodt plc ha Valore dell'impresa di $25.90M
- Alien Metals ha Valore dell'impresa di $25.91M
- Vst Building Techs Ag ha Valore dell'impresa di $25.92M
- Invitrocue ha Valore dell'impresa di $25.93M